Navigation Links
The Female Health Company Reports First Quarter Operating Results, as Gross Profit Margins Widen on Increasing Sales of FC2 Female Condom(R)

CHICAGO, Feb. 10 /PRNewswire-FirstCall/ -- The Female Health Company (NYSE Alternext: FHC), which manufactures and markets the FC and FC2 Female Condoms(R), today reported its operating results for the first quarter of FY2009.

While unit sales increased during the three months ended December 31, 2008, the Company's net revenues decreased 7% to approximately $5.3 million, compared with approximately $5.7 million in the first quarter of the previous fiscal year. The decline in revenues reflects a continuing shift in product shipments towards the Company's FC2 Female Condom(R), which is priced lower and generates a higher gross profit margin than FC1. In addition, unit sales have been temporarily limited by a significant increase in orders for FC1, our first generation product, by customers requiring final FDA approval to order FC2. At times, the increased demand has exceeded our capacity to produce FC1. We elected not to invest in expanding FC1 production capacity in anticipation of securing FC2 FDA approval, discontinuing FC1 and investment in expanding FC2 production capacity. Given final FDA approval, it is anticipated that these customers will purchase FC2, eliminating this temporary limitation.

The Company's net income attributable to common shareholders increased 98% to $1,608,816, or $0.06 per diluted share, during the first quarter of FY2009, compared with net income attributable to common shareholders of $813,968, or $0.03 per share, in the corresponding period of the previous fiscal year. The Company was positively impacted by the strengthening of the U.S. dollar relative to the British pound sterling in the first quarter of FY2009, resulting in a foreign currency gain of $1,194,107, compared with a currency gain of $115,358 in the first quarter of FY2008.

Gross profit increased 3% to $2,441,194 in the most recent quarter, compared with $2,366,116 in the first quarter of FY2008. Gross profit as a percentage of revenue totaled 45.7% in the first quarter of FY2009, versus 41.3% in first quarter of FY2008. Operating income decreased to $438,935, from $729,645 in the three months ended December 31, 2007, due in part to significant one-time expenses related to the Company's preparation for, and participation in, the FDA OB/GYN Device Advisory Committee hearing on December 11, 2008. Other expense increases included compensations costs and Sarbanes Oxley internal control review consulting.

As noted in previous news releases, the Company expects significant quarter-to-quarter variations in its operating results, due to the timing of large order receipts, production scheduling, and shipping of products.

"We are pleased with first quarter results, which were consistent with management's expectations," noted O.B. Parrish, Chief Executive Officer of The Female Health Company. "The increasing acceptance of our second-generation FC2 Female Condom(R) and its favorable impact on our profitability is particularly encouraging. We ended the first quarter with a strong, debt-free balance sheet, approximately $3.3 million of cash in the bank, and a current ratio of 4.3-to-1.0."

"The event of greatest significance during our first quarter occurred in December, when the FDA's OB/GYN Advisory Panel voted unanimously to recommend approval of FC2, so long as the labeling specifies the type of clinical study on which the approval was based. We are presently working through labeling details with the FDA for final approval, which will allow us to market FC2 in the United States and to provide it to the U.S. Agency for International Development (USAID), one of our largest customers."

"We are reaffirming our annual guidance for FY 2009 that unit sales should increase 20% to 25% and that operating earnings should rise 50% to 75% from last year's record levels," concluded Parish.

As previously announced, the Female Health Company will host an investor conference call at 11:00 a.m. EST today, February 10, 2009. Shareholders and other interested parties may participate in the conference call by dialing 800-860-2442 (international participants dial 412-858-4600) and asking to be connected to "The Female Health Company Conference Call", a few minutes before 11:00 a.m. EST on February 10, 2009. A replay of the call will be available one hour after the call through 5:00 p.m. EST on February 24, 2009 by dialing 877-344-7529 (international callers dial 412-317-0088) and entering the conference ID 427502.

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC Female Condom(R), (FC1) and the FC2 Female Condom (FC2), which are primarily distributed by public health organizations and donor groups in over 90 developing countries around the world. Globally, the Female Condoms are available in various programs in 116 countries. The Company owns certain worldwide rights to the FC Female Condom(R), including patents that have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, the European Patent Convention, the People's Republic of China, Canada, South Korea and Australia. FC Female Condom(R) is the only available FDA- approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy.

For more information about the Female Health Company visit the Company's web site at and If you would like to be added to an e-mail alert list, please send an e-mail to

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical fact are "forward- looking statements" as that term in defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release include the Company's financial guidance for fiscal 2009. These statements are based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties. The Company's actual results and future developments could differ materially from the results or developments express in, or implied by, these forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; The Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments; global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures, risks involved in doing business on an international level, including currency risks, regulator requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communication and Securities and Exchange Commission filings, including the Company's form 10-K for the fiscal year ended September 30, 2008. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

                          The Female Health Company
               Unaudited Condensed Consolidated Balance Sheets

                                                   December 31,  December 31,
                                                      2008          2007
    Cash                                          $3,190,841     $1,604,306
    Restricted cash                                  173,970        236,138
    Accounts receivable, net                       3,444,439      6,007,114
    Inventory                                      1,817,324      1,785,430
    Prepaid and other current assets                 282,884        328,516
    Deferred income taxes                          1,600,000        825,000
    Total current assets                          10,509,458     10,786,504

    Other non-current assets                          56,000        246,853
    Net property, plant & equipment                1,446,858      1,477,667
    Total assets                                 $12,012,316    $12,511,024

    Accounts payable                              $1,047,221     $1,129,725
    Accrued expenses                               1,374,249      1,818,791
    Preferred dividends payable                       24,575         48,643
    Total current liabilities                      2,446,045      2,997,159

    Obligations under capital leases                  30,573         58,888
    Deferred gain on sale of facilities              666,233      1,017,317
    Deferred grant income                            161,382        247,567
    Total liabilities                              3,304,233      4,320,931

    Total stockholders' equity                     8,708,083      8,190,093
    Total liabilities and stockholders' equity   $12,012,316    $12,511,024

                          The Female Health Company
              Unaudited Condensed Consolidated Income Statements

                                                      Three Months Ended
                                                         December 31,
                                                      2008          2007

    Net revenues                                  $5,344,838     $5,734,751

    Cost of products sold                          2,903,644      3,368,635

    Gross profit                                   2,441,194      2,366,116

    Advertising and promotion                         70,794         41,518
    Selling, general and administrative            1,861,045      1,493,824
    Research and development                          70,420        101,129

    Total operating expenses                       2,002,259      1,636,471

    Operating income                                 438,935        729,645

    Interest, net and other income                    (8,889)        (9,608)
    Foreign currency transaction gain             (1,194,107)      (115,358)
    Income before income taxes                     1,641,931        854,611

    Income tax expense                                 8,540              -

    Net income                                     1,633,391        854,611

    Preferred dividends                               24,575         40,643

    Net income attributable to common
     stockholders                                 $1,608,816       $813,968

    Net income per basic common share outstanding      $0.06          $0.03

    Basic weighted average common shares
     outstanding                                  25,820,224     26,121,460

    Net income per diluted common share outstanding    $0.06          $0.03

    Diluted weighted average common shares
     outstanding                                  27,984,633     28,688,345

SOURCE The Female Health Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Female Hormones Deter Salt-Sensitive Hypertension
2. The Female Health Company Schedules First Quarter Conference Call for February 10, 2009
3. Living with females extends the reproductive life of the male mouse, says Penn veterinary researcher
4. FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable
5. Surprising Results on Smoking Research Hispanic Versus White Female Smokers
6. Latin American and U.S. Latina Women Unite to Demand Access to the Female Condom
7. The Female Health Company Schedules Year End FY2008 Conference Call for December 1, 2008
8. Surprisingly, female models have negative effect on men
9. Large-Scale Survey Reveals Low Sexual Desire Most Common Distressing Female Sexual Problem, Affecting Up to One in 10 Women
10. Sexual Trauma Haunts Many Female Vets
11. The Health Insurance Advocate Radio Show Expands to Springfield, Missouri, and Reaches a New All-Time Ratings High for Female Listenership
Post Your Comments:
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will ... the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey ... Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... SAN DIEGO , Oct. 12, 2017 ... has recognized the company with their  2017 New Product Innovation ... is based on extensive primary and secondary medical device market ... AVACEN Medical, through its first-to-market OTC, drug-free pain relief product, ... a unique approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
Breaking Medicine Technology: